Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gyre TherapeuticsGYRE -1.20%39 3-Year EBITDA Growth Rate is 0.20% as of Jun. 2026. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.42 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,127 Biotechnology companies, Gyre Therapeutics ranks worse than 69.12% on this metric.
During the past 12 months, Gyre Therapeutics's average EBITDA Per Share Growth Rate was -237.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 0.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Gyre Therapeutics was 0.20% per year. The lowest was -25.00% per year. And the median was -12.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Gyre Therapeutics 3-Year EBITDA Growth Rate Related Terms
GYRE vs OCS, RIGL, SGP: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Gyre Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.20% mean?
Gyre Therapeutics (GYRE) has a 3-Year EBITDA Growth Rate of 0.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gyre Therapeutics and its competitors. According to the industry distribution chart, Gyre Therapeutics ranks #779 out of 1127 companies in the Biotechnology industry, placing it in the top 69.1%.
Is Gyre Therapeutics' 3-Year EBITDA Growth Rate too high?
Gyre Therapeutics' current 3-Year EBITDA Growth Rate is 0.20%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Gyre Therapeutics' value of 0.20% is 98.7% below this industry median. Based on the distribution chart, Gyre Therapeutics ranks #779 out of 1127 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' 3-Year EBITDA Growth Rate compare to OCS and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #779 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Gyre Therapeutics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Gyre Therapeutics' value of 0.20% is 98.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current 3-Year EBITDA Growth Rate of 0.20% is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gyre Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current 3-Year EBITDA Growth Rate is 0.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Possible Value Trap. The stock's GF Value™ is $9.42, compared to a current price of $6.59 — trading 30% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.20% and 98.7% below the Biotechnology industry median of 14.90. Gyre Therapeutics' overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current 3-Year EBITDA Growth Rate is 0.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.59 is trading 30% below its estimated GF Value™ of $9.42.
GuruFocus considers Gyre Therapeutics to be Possible Value Trap.
Key valuation signals for GYRE:
3-Year EBITDA Growth Rate: 0.20%
GF Value™: $9.42 vs. price of $6.59 (30% below fair value)
Industry Position: 98.7% below the Biotechnology median (#779 of 1127)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
